Id Biomedical Corporation

Id Biomedical Corporation of Quebec

Biochem Pharma Inc.

Biochem Vaccines Inc.

Shire Biochem, Inc.

Stephane Rioux

Bernard R. Brodeur

Josee Hamel

Denis Martin

Martine Boyer

Bernard R Brodeur

Clement Rioux

Patrick Rheault

Nathalie Charland

Isabelle Pineau

Isabelle Charlebois

Diane Bussiere

The present invention relates to antigens more particularly antigens of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.

Streptococcus pyogenes antigens and corresponding DNA fragments

The present invention relates to antigens, more particularly antigenS of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.

[object Object]

The present invention relates to antigens, more particularly antigens of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.

The present invention relates to antigens, more particularly antigens of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.

The identification of a highly conserved, immunologically accessible antigen at the surface offacilitates treatment, prophylaxis, and diagnosis ofdiseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from threestrains and from onestrain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of thesurface protein, and antibodies that bind to this protein are also disclosed.

The present invention relates to antigens, more particularly an antigen of(also called group A(GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.

proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingbacterial infection.

The present invention relates to antigens, more particularly antigens of(also called group A(GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis. 

The present invention relates to polypeptides ofwhich may be used to prevent, diagnose and/or treatinfection.

The identification of a highly conserved, immunologically accessible antigen on the surface offacilitates treatment, prophylaxis, and diagnosis ofdiseases. This antigen is highly resistant to proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from threestrains and from onestrain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of thesurface protein, and antibodies that bind to this protein are also disclosed.

Growing community of inventors

Sillery, Canada

Josee Hamel